PROVETOP

Biotinylated Cynomolgus FcRH5/FcRL5 Domain Protein (Primary Amine Labeling)

Catalog No: FCRH5FCRL5DOMAIN-CB001

Species
Cynomolgus
Expression System
HEK293
Tag
His
Activity
Activity verified

Product overview

Recombinant Biotinylated Cynomolgus FcRH5/FcRL5 Domain Protein is expressed in HEK293 cells with a His tag at the N-terminus. It contains amino acid residues Val745-Thr850 (accession: XP_005541423.2).

Product Details

Molecular Aliases
FcR-like protein 5; FcRH5; FcRL5; BXMAS1; CD307; CD307e; IFGP5; IRTA2
Protein Length
Val745-Thr850
Expression System
HEK293
Theoretical Molecular Weight
The protein has a predicted MW of 12.3 kDa. Due to glycosylation, the protein migrates to 27-35 kDa based on Bis-Tris PAGE result.
Purity
> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
Endotoxin
Less than 1 EU per μg by the LAL method.
Buffer / Formulation
Supplied as 0.22 μm filtered solution in PBS (pH 7.4).
State
Liquid
Storage Conditions
Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Data Display

Bis-Tris PAGE
FCRH5FCRL5DOMAIN-CB001 Bis-Tris-PAGE-white result

Biotinylated Cynomolgus FcRH5 Domain on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC
FCRH5FCRL5DOMAIN-CB001 SEC-HPLC result

The purity of Biotinylated Cynomolgus FcRH5 Domain is greater than 95% as determined by SEC-HPLC.

ELISA
FCRH5FCRL5DOMAIN-CB001 ELISA result

Immobilized Biotinylated Cynomolgus FcRH5 Domain, His Tag at 0.5μg/ml (100μl/Well) on streptavidin (5μg/ml) precoated plate. Dose response curve for Anti-FcRH5 Antibody, hFc Tag with the EC50 of 14.0ng/ml determined by ELISA. (QC Test)

Background

FcRH5 is a cell surface marker enriched on malignant plasma cells when compared to other hematologic malignancies and normal tissues. DFRF4539A is an anti-FcRH5 antibody-drug conjugated to monomethyl auristatin E (MMAE), a potent anti-mitotic agent.

References

  1. Elkins K, Zheng B, Go M, et al. FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma. Mol Cancer Ther. 2012;11(10):2222-2232. doi:10.1158/1535-7163. MCT-12-0087.

Have questions about this product?

Our technical team can help with product selection, application questions and order support.

Contact Technical Support